<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713295</url>
  </required_header>
  <id_info>
    <org_study_id>P15-693</org_study_id>
    <nct_id>NCT02713295</nct_id>
  </id_info>
  <brief_title>A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece</brief_title>
  <acronym>CONCORDIA</acronym>
  <official_title>A Non-interventional Prospective Cohort Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study estimates the treatment goal achievement rate, depicts the implementation of the
      Progressive Psoriasis Initiative (PPI) recommendations regarding treatment modifications and
      transitioning, and assesses patient adherence and persistence with adalimumab therapy in the
      routine clinical practice in Greece.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2016</start_date>
  <completion_date type="Actual">April 19, 2019</completion_date>
  <primary_completion_date type="Actual">April 19, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who will achieve the European Consensus Programme (ECP)-defined treatment goals at the end of the induction phase (i.e. 16 weeks post-treatment onset)</measure>
    <time_frame>16 weeks post-treatment</time_frame>
    <description>Achievement of the treatment goals during the induction phase is defined as:
Treatment Success: i.e. &gt;=75% Psoriasis Area Severity Index (PASI) score reduction OR
Intermediate Response with Dermatology Life Quality Index (DLQI) &lt;=5: i.e. PASI score reduction &gt;=50% but &lt;75% with DLQI &lt;=5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving intermediate response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Intermediate response is defined as participants with PASI score reduction &gt;=50% but &lt;75% compared to week 0 (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participant achieving treatment success</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Treatment success rate is defined as participants with &gt;=75% PASI score reduction compared to week 0 (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participant with treatment failure</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Treatment failure is defined as participants with PASI score reduction &lt;50% compared to week 0 (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving the treatment goals</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>According to the European Consensus Programme (ECP) guidelines, achievement of the treatment goals during the maintenance phase is defined as:
Treatment Success: i.e. &gt;=75% Psoriasis Area Severity Index (PASI) score reduction compared to the time of therapy initiation (i.e. baseline) (or)
Intermediate Response with Dermatology Life Quality Index (DLQI) &lt;=5: i.e. PASI score reduction &gt;=50% but &lt;75% compared to baseline, with DLQI &lt;=5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first missed dose during the study observation period</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Patient diary will be reviewed to assess this information</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">273</enrollment>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Subjects with Moderate to Severe Plaque Psoriasis</arm_group_label>
    <description>Subjects with Moderate to Severe Plaque Psoriasis in Greece</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Moderate to Severe Plaque Psoriasis in Greece
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of plaque psoriasis for at least 6 months, and moderate to severe
             disease course at the time of adalimumab treatment onset, defined as Body Surface Area
             (BSA) &gt;10 or PASI &gt;10 and DLQI &gt;10

          -  Patients for whom the decision to prescribe therapy with adalimumab (HumiraÂ®)
             according to the locally approved summary of product characteristics (SmPC) has
             already been taken prior to their enrolment in the study and is clearly separated from
             the physician's decision to include the patient in the current study

          -  Patients with an available Psoriasis Area Severity Index (PASI) and Dermatology Life
             Quality Index (DLQI) scores at the start of adalimumab treatment

          -  Patients able and willing to provide written informed consent and to comply with the
             requirements of this study protocol

          -  Patients with a signed informed consent document

        Exclusion Criteria:

          -  Patients should not have non-plaque forms of psoriasis (e.g., erythrodermic, guttate,
             or pustular)

          -  Patients for whom treatment with adalimumab has been initiated more than 2 weeks prior
             to their enrolment into the study

          -  Patients that meet any of the contraindications to the administration of the study
             drug according to the latest version of the locally approved SmPC

          -  Patients who have previously been exposed to adalimumab unless a period of at least 6
             months from the last dose has elapsed

          -  Patients currently receiving treatment with any investigational
             drug/device/intervention or who have received any investigational product within 1
             month or 5 half-lives of the investigational agent (whichever is longer) before the
             commencement of therapy with adalimumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Univ Hosp &quot;Attikon&quot; /ID# 149517</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tzaneio general hospital of Piraeus /ID# 149518</name>
      <address>
        <city>Piraeus</city>
        <state>Attiki</state>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Uni hosp of Larissa /ID# 149688</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>415 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Uni hosp of Larissa /ID# 151442</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>415 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Konstantinos Tsaousis /ID# 149704</name>
      <address>
        <city>Amaliada</city>
        <zip>27200</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Maria Sifaki /ID# 149717</name>
      <address>
        <city>Arkalochori</city>
        <zip>70300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Ekaterini Galaterou /ID# 149713</name>
      <address>
        <city>Athens, AGIA Paraskeui</city>
        <zip>15343</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Ioannis Papaggelopoulos /ID# 149703</name>
      <address>
        <city>Athens, Ampelokipi</city>
        <zip>11626</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Antonios Seretis /ID# 149714</name>
      <address>
        <city>Athens, Chalandri</city>
        <zip>15231</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Despoina Arnaoutoglou /ID# 149707</name>
      <address>
        <city>Athens, Glyfada</city>
        <zip>16562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Maria Loukatou /ID# 149706</name>
      <address>
        <city>Athens, Glyfada</city>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Eirini Stefanaki /ID# 149695</name>
      <address>
        <city>Athens, NEA Filadelfeia</city>
        <zip>14341</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Pantelis Aronis /ID# 149705</name>
      <address>
        <city>Athens, NEA Smyrni</city>
        <zip>17124</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Theognosia Vergou /ID# 149694</name>
      <address>
        <city>Athens, VARI</city>
        <zip>16672</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Ioannis Mparkis /ID# 149711</name>
      <address>
        <city>Athens,neo Irakleio</city>
        <zip>14121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 158934</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Michael Kakepis /ID# 149693</name>
      <address>
        <city>Athens</city>
        <zip>10682</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Georgios Papadopoulos /ID# 149712</name>
      <address>
        <city>Athens</city>
        <zip>11251</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Ioannis Krikellis /ID# 149715</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Markos Papakonstantis /ID# 149702</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Panagiotis Deligiannis /ID# 149708</name>
      <address>
        <city>Athens</city>
        <zip>11634</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genl Hospital Andreas Syggros /ID# 149516</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genl Hospital Andreas Syggros /ID# 149687</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Vasilios Chatzakis /ID# 149718</name>
      <address>
        <city>Crete, Heraklion</city>
        <zip>71201</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Kalliopi Karamanolaki /ID# 149720</name>
      <address>
        <city>Crete, Heraklion</city>
        <zip>71305</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Vasiliki Tzirka /ID# 149722</name>
      <address>
        <city>Drama</city>
        <zip>66100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kontargiris, MD, Kalamata, GR /ID# 151444</name>
      <address>
        <city>Kalamata</city>
        <zip>24100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konstantopouleio General Hospi /ID# 149690</name>
      <address>
        <city>Nea Ionia</city>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Konstantinos Markakis /ID# 149723</name>
      <address>
        <city>Orestiada</city>
        <zip>68200</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigatos, MD, Patra, GR /ID# 151446</name>
      <address>
        <city>Patras</city>
        <zip>26221</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gen Hosp of Patra /ID# 149691</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Chrysa Zisimou Politopou /ID# 149728</name>
      <address>
        <city>Stylida</city>
        <zip>35300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Aimilios Lallas /ID# 149721</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54623</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Pantelis Souvantzidis /ID# 149726</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54623</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Stelios Charalampidis /ID# 149727</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54623</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Georgios Chaidemenos /ID# 149724</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloni /ID# 149692</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55134</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kallidis, MD, Thessaloniki, GR /ID# 151443</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55236</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki George Papanikolaou /ID# 149515</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manousari, MD, Veroia, GR /ID# 151445</name>
      <address>
        <city>Veroia</city>
        <zip>59132</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Prodromos Christoforidis /ID# 149730</name>
      <address>
        <city>Volos</city>
        <zip>38221</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Xanthi /ID# 149519</name>
      <address>
        <city>Xanthi</city>
        <zip>67100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PP of Stathis Gkourvelos /ID# 149709</name>
      <address>
        <city>Xilokastro</city>
        <zip>20400</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.abbvie.com/content/dam/abbvie-dotcom/clinical-trials/adalimumab_P15-693.pdf</url>
    <description>clinical study report synopsis</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Plaque Psoriasis</keyword>
  <keyword>Severe Plaque Psoriasis</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

